Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 12/20 | 0.49 |
| ▸ | UBA3 | Q8TBC4 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | UBA6 | A0AVT1 | 2/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192849 | 1.00 | NAE1 (0.49) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL10004894 | 0.89 | PRMT5 (0.37) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL10004893 | 0.89 | PRMT5 (0.37) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL192272 | 0.89 | PRMT5 (0.37) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL12988072 | 0.86 | PRMT5 (0.39) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL192062 | 0.86 | PRMT5 (0.39) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL192061 | 0.86 | PRMT5 (0.39) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL12988075 | 0.86 | PRMT5 (0.39) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL192354 | 0.83 | NAE1 (0.67) | NAE1UBA3CA2UBA6GRK5 | |
| SCHEMBL18837020 | 0.83 | NAE1 (0.35) | NAE1UBA3CA2UBA6GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885CA2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.